VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
Part of paid clinical trials in Hartford, Connecticut.
- Sponsor
- National Cancer Institute (NCI)
- Study ID
- NCT00462826
- Phase
- PHASE2
- Status
- Completed
Conditions
- Recurrent Endometrial Carcinoma
Eligibility Criteria
- Sex
- FEMALE
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- ziv-aflibercept — BIOLOGICAL
Study Details
This phase II trial is studying the side effects and how well VEGF Trap works in treating patients with recurrent or persistent endometrial cancer. VEGF Trap may stop the growth of endometrial cancer by blocking blood flow to the tumor and by carrying tumor-killing substances directly to endometrial cancer cells.
Key Dates
- Start date
- Nov 30, 2007
- Status verified
- Jul 2019
- Primary completion
- Jan 31, 2013
- Completion
- Jan 31, 2013
Study Design
- Enrollment
- 49 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Treatment (aflibercept)Patients receive VEGF Trap IV over 1 hour on days 1 and 15. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
Primary Outcome Measure
6 Month Progression-free Survival [ Time Frame: At 6 monthsEvery other cycle during treatment for the first 6 months. ]
Locations (67)
Find similar trials in Hartford, CT
Related Studies
- Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic CancersPHASE1 · Recruiting · M.D. Anderson Cancer Center · Baltimore, Maryland
- Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial CarcinomaPHASE2 · Recruiting · National Cancer Institute (NCI) · Birmingham, Alabama
- Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment TrialPHASE2 · Recruiting · National Cancer Institute (NCI) · Birmingham, Alabama
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening TrialPHASE2 · Recruiting · National Cancer Institute (NCI) · Birmingham, Alabama